<DOC>
	<DOCNO>NCT01702974</DOCNO>
	<brief_summary>The aim study provide immunotherapy vitamin D phenylbutyrate treatment-naive HIV infect patient induce important antimicrobial defence mechanism decrease inflammation .</brief_summary>
	<brief_title>Immune Reconstitution HIV Disease ( IREHIV )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<criteria>Adult patient &gt; 18 year subject HAART . HIV1 infect patient CD4 T cell count &gt; 200 cells/ml . Detectable plasma viral load &gt; 1000 copies/ml . Patients HAART antimicrobial drug ( include bactrim ) . Antimicrobial drug treatment past month . Patients medical contraindication biopsy bleed tendency . Hypercalcaemia ( serum calcium &gt; 3,0 mmol/L ) identify baseline . Pregnant breast feed woman . Any known liver kidney function abnormality , malignancy patient treat cardiac glycoside .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>cholecalciferol</keyword>
	<keyword>sodium phenylbutyrate</keyword>
	<keyword>antimicrobial peptide</keyword>
	<keyword>immune response</keyword>
	<keyword>inflammation</keyword>
</DOC>